China's Pharmaceutical Innovation Enters a 'Golden Era' as R&D Investments Rapidly Translate into Clinical Achievements

　　【Pharmaceutical Network Industry DynamicsIn recent years, under the era opportunity of China listing biomedicine as an emerging pillar industry, the R&D quality and quantity of domestically produced innovative drugs in China are continuously improving. It is reported that by the end of March, a large number of domestically produced innovative drugs had been approved for clinical trials, covering many fields such as primary IgA nephropathy, inflammation, and advanced solid tumors.
 

On March 31, Shanghai Henlius Biotech, Inc. announced that the Investigational New Drug (IND) application for HLXTE-HAase02 (Recombinant Human Hyaluronidase Injection) ("HLXTE-HAase02"), a product independently developed by the company, had been approved by the National Medical Products Administration (NMPA) recently.
 

According to reports, HLXTE-HAase02 is a novel recombinant human hyaluronidase (rHuPH20) independently developed by the company, intended for promoting the dispersion and absorption of subcutaneously injected or infused drugs. As of February 2026, the company's cumulative R&D investment in this drug amounts to approximately RMB 26.73 million (unaudited).
 

On March 31, Kerui Biotech announced that its self-developed TCR-TCE (T-cell receptor-T-cell engager) innovative drug, CRPA1A2 Injection, had received clinical trial tacit approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). This approval marks the official entry of Kerui Biotech's first TCR-TCE product into the clinical research stage in China. Previously, CRPA1A2 had already obtained FDA IND approval in December 2025.
 

Notably, the TCR molecule adopted by CRPA1A2 is derived from Beijing Kerui Biological Technology Co., Ltd.'s self-developed SMART-TCR® affinity optimization platform. This platform significantly enhances TCR affinity and functional activity while rigorously screening out potentially cross-reactive clones, ensuring excellent specificity for the MAGE-A1/HLA-A02:01 complex.
 

On the same day, CHANGCHUN HIGH-TECH announced that Changchun GeneScience Pharmaceutical Co., Ltd., a subsidiary, had received approval for the clinical trial application of GenSci161 Injection as a domestically produced drug in China. GenSci161 Injection is a Class 1 biologic therapeutic independently developed by GenSci, intended for the treatment of endometriosis and moderate to severe hidradenitis suppurativa.
 

In addition, Fosun Pharmaceutical recently announced that its holding subsidiary, Shanghai Henlius Biotech, Inc., has received approval from the National Medical Products Administration (NMPA) to conduct a Phase I clinical trial for HLXTE-HAase02 (recombinant human hyaluronidase injection), which is intended to promote the dispersion and absorption of subcutaneously injected or infused drugs. On the same day, the company also announced that another holding subsidiary, Fosun Pharmaceutical Industry, received NMPA approval to initiate clinical trials for FXB0871 in patients with locally advanced or metastatic solid tumors.
 

　　……
 

Overall, since 2026, the R&D investment of leading pharmaceutical companies in China has been accelerating the transformation into clinical outcomes. These drugs also reflect the current trends in China's pharmaceutical industry: diversified technological routes, prominent platform value, and improved R&D efficiency. In the future, as more "world-first" drugs enter clinical trials, the "golden age" of pharmaceutical innovation in China is expected to arrive at an accelerated pace.
 

　　Disclaimer: In no event shall the information or opinions expressed in this article constitute investment advice to any person.